Eculizumab: all 80 studies that test it
Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Safety and Efficacy of Eculizumab in High-risk TA-TMARecruitingNCT07707687Phase 2
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingNCT07010302Phase 4
- Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney TransplantationNot yet recruitingNCT06453135Phase 1/2
- Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic SyndromeRecruitingNCT05726916Phase 3
- Study of NM8074 in Adult PNH Patients With Inadequate Response to SolirisNot yet recruitingNCT05646563Phase 2
- Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaCompletedNCT05886244Phase 3Results posted
- Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in ChinaCompletedNCT05876351Phase 3Results posted
- A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré SyndromeCompletedNCT04752566Phase 3Results posted
- Complement Regulation to Undo Systemic Harm in PreeclampsiaTerminatedNCT04725812Phase 2Results posted
- Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose EculizumabCompletedNCT04320602Phase 4Results posted
- A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum DisorderTerminatedNCT04155424Phase 2/3Results posted
- A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal HaemoglobinuriaCompletedNCT04058158Phase 3Results posted
- Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®CompletedNCT04027803Phase 1Results posted
- A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNHCompletedNCT03818607Phase 3Results posted
- A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)CompletedNCT03759366Phase 3Results posted
- Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant RecipientsCompletedNCT03518203Phase 2Results posted
- Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to EculizumabCompletedNCT03472885Phase 2Results posted
- Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia GravisCompletedNCT02301624Phase 3Results posted
- Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe ThrombocytopeniaCompletedNCT02298933Phase 2Results posted
- Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)CompletedNCT02145182Phase 2/3Results posted
- The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac TransplantationCompletedNCT02013037Phase 3Results posted
- An Open Label Extension Trial of Eculizumab in Relapsing NMO PatientsCompletedNCT02003144Phase 3Results posted
- Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)CompletedNCT01997229Phase 3Results posted
- Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal TransplantationTerminatedNCT01895127Phase 2Results posted
- A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)TerminatedNCT01892345Phase 3Results posted
- Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased DonorCompletedNCT01567085Phase 2Results posted
- Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring DesensitizationTerminatedNCT01399593Phase 2Results posted
- Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney TransplantationCompletedNCT01327573Phase 1Results posted
- Eculizumab Therapy for Dense Deposit Disease and C3 NephropathyCompletedNCT01221181Phase 1Results posted
- An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic SyndromeCompletedNCT01194973Phase 2Results posted
- E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria PatientsCompletedNCT01194804Phase 2Results posted
- An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic SyndromeCompletedNCT01193348Phase 2Results posted
- Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria PatientsCompletedNCT01192399Phase 2Results posted
- Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney TransplantTerminatedNCT01106027Phase 1/2Results posted
- Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney TransplantationTerminatedNCT01095887Phase 1/2Results posted
- Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody SyndromeCompletedNCT01029587Phase 2Results posted
- Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)CompletedNCT00935883Phase 2Results posted
- An Open Label Study of the Effects of Eculizumab in Neuromyelitis OpticaCompletedNCT00904826Phase 1/2Results posted
- Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT00867932Phase 4Results posted
- Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUSCompletedNCT00844844Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUSCompletedNCT00844545Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUSCompletedNCT00844428Phase 2Results posted
- Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT00838513Phase 2Results posted
- Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia GravisTerminatedNCT00727194Phase 2Results posted
- Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney TransplantCompletedNCT00670774Phase 1/2Results posted
- Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT00122317Phase 3Results posted
- Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum DisorderActive, not recruitingNCT07184840Phase 2
- An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURNCompletedNCT06987864Phase 3
- Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMGCompletedNCT06764160Phase 3
- Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSDActive, not recruitingNCT06724809Phase 3
- Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum DisorderWithdrawnNCT06673394Phase 2
- A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor TherapyCompletedNCT06593938Phase 3
- Complement C5 mAb in the Treatment of Anti-GBM DiseaseCompletedNCT06513338Phase 2
- A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation)CompletedNCT04679103Phase 3
- Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNHCompletedNCT04463056Phase 3
- CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 CohortStatus unknownNCT04346797Phase 2
- The Use of Eculizumab in HELLP SyndromeCompletedNCT04103489Phase 1
- Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy SubjectsCompletedNCT03722329Phase 1
- Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver TransplantationWithdrawnNCT03468140Early Phase 1
- Complement Inhibitor Eculizumab in Clinical Islet TransplantationCompletedNCT02727608Phase 2
- Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUSCompletedNCT02574403Phase 4
- JET-GBS - Japanese Eculizumab Trial for GBSCompletedNCT02493725Phase 2
- Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHUCompletedNCT02205541Phase 3
- Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney TransplantationWithdrawnNCT02113891Phase 1/2
- Eculizumab in Primary MPGNCompletedNCT02093533Phase 2
- Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome StudyStatus unknownNCT02029378Phase 2
- Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney TransplantationTerminatedNCT01919346Phase 2
- The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)CompletedNCT01757431Phase 2
- Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion InjuryCompletedNCT01756508Phase 2
- An Open Label Study of the Effects of Eculizumab in CD59 DeficiencyStatus unknownNCT01579838Phase 1/2
- Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)CompletedNCT01410916Phase 2/3
- A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney TransplantTerminatedNCT01403389Phase 2
- Therapy of Chronic Cold Agglutinin Disease With EculizumabCompletedNCT01303952Phase 2
- Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - EculizumabWithdrawnNCT01275287Phase 2
- Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic AsthmaCompletedNCT00485576Phase 2
- Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00130000Phase 3
- Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) PatientsCompletedNCT00122330Phase 3
- Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With EculizumabCompletedNCT00122304Phase 3
- Eculizumab in Treating Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00112983Phase 3
- Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaCompletedNCT00098280Phase 3